Celltrion’s Zymfentra shows consistent efficacy across Crohn’s disease subtypes

South Korea’s Celltrion announced on Nov. 26 that a post-hoc analysis of its global Phase 3 clinical trial for Zymfentra has been published in a leading international medical journal.

As the subcutaneous formulation of infliximab marketed in the United States as Remsima SC, Zymfentra is prescribed for autoimmune conditions, including Crohn’s disease.

The newly released findings come from additional analysis of the LIBERTY-CD study and were published in Clinical Gastroenterology and Hepatology, placing it among the top 6 percent of publications in its field.

A post-hoc analysis is a secondary examination of clinical trial data conducted after the main results are finalized. It often provides deeper insights into treatment effects across specific patient subgroups, according to Celltrion.

In this case, researchers reviewed endoscopic results by both anatomical regions and more specific intestinal segments, including the terminal ileum, left colon, transverse colon, right colon, and rectum.

The original LIBERTY-CD trial investigated whether infliximab SC could outperform placebo in maintaining remission among patients with moderate to severe active Crohn’s disease, Celltrion said.

Crohn’s disease, a chronic inflammatory bowel disorder, is classified according to the primary location of inflammation.

“The results demonstrate that Zymfentra provides consistent therapeutic benefits regardless of the inflammation site, potentially overcoming the limitations of current treatment options,” a Celltrion representative said.

“We intend to expand prescriptions and improve the quality of life for more patients by leveraging the drug’s convenience and strong clinical performance.”